No Data
Additional Considerations Required While Assessing Xiamen Amoytop Biotech's (SHSE:688278) Strong Earnings
Xiamen Amoytop Biotech Q3 Profit Up 50%, Revenue Rises 38%
Tebao Biotech: Third quarter report 2024
Xiamen Amoytop Biotech (688278.SH) released its performance for the first three quarters, with a net income of 0.554 billion yuan, a year-on-year increase of 50.21%.
Xiamen Amoytop Biotech (688278.SH) disclosed the third quarter report for 2024, with the company achieving revenue of 19...
Xiamen Amoytop Biotech (688278.SH): The net income for the first three quarters was 0.554 billion yuan, a year-on-year increase of 50.21%.
On October 24th, Gelonghui reported that Xiamen Amoytop Biotech (688278.SH) released its third quarter report for 2024, with the company's revenue in the first three quarters reaching 1.955 billion yuan, a year-on-year increase of 33.90%; the net income attributable to shareholders of the listed company was 0.554 billion yuan, a year-on-year increase of 50.21%; the net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 0.581 billion yuan, a year-on-year increase of 41.34%; with an EPS of 1.36 yuan.
Xiamen Amoytop Biotech Co., Ltd. (SHSE:688278) Insiders Have Significant Skin in the Game With 51% Ownership
Here's Why We Think Xiamen Amoytop Biotech (SHSE:688278) Might Deserve Your Attention TodayNo Data
No Data
